We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current CSPCY market cap is 10.21B. The company's latest EPS is CNY 1.9737 and P/E is 0.43.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CNY (元) | CNY (元) | CNY (元) | CNY (元) | CNY (元) | |
| Total Revenue | 22.1B | 24.94B | 27.87B | 30.94B | 31.45B |
| Operating Income | 4.55B | 5.59B | 6.39B | 7.03B | 7.08B |
| Net Income | 3.71B | 5.16B | 5.61B | 6.09B | 5.87B |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CNY (元) | CNY (元) | CNY (元) | CNY (元) | CNY (元) | |
| Total Assets | 26.32B | 30.07B | 34.74B | 41.77B | 46.28B |
| Total Liabilities | 6.8B | 6.97B | 7.91B | 10.13B | 11.26B |
| Total Equity | 19.52B | 23.1B | 26.83B | 31.64B | 35.02B |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CNY (元) | CNY (元) | CNY (元) | CNY (元) | CNY (元) | |
| Operating | 3.78B | 6.74B | 4.64B | 7.63B | 4.18B |
| Investing | -2.46B | -2.13B | -637.33M | -6.8B | 607.27M |
| Financing | -1.55B | -1.47B | -2.2B | -1.9B | -2.3B |
| Market Cap | 10.21B |
| Price to Earnings Ratio | 0.43 |
| Price to Sales Ratio | 0.08 |
| Price to Cash Ratio | 0.24 |
| Price to Book Ratio | 0.07 |
| Dividend Yield | - |
| Shares Outstanding | 2.98B |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 0.15 (4.31%) |
| Company Name | Cspc Pharmaceuticals Group Ltd (PK) |
| Address |
suite 3206, 32/f wan chai, wan chai |
| Website | https://www.irasia.com/listco/hk/cspc |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
